153 completed, 51 terminated, 36 recruiting, 31 active not recruiting. 321 Phase 2, 71 Phase 1, 12 Phase 3.
Follow Bladder Cancer: new trials by email Literature Review of Bladder Cancer trials Research Report on Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Naloxegol in the Prevention of POI After Cystectomy Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications | Phase 2 | Withdrawn | Institut Paoli-Calmettes | 2032-01-01 | 2026-10-14 | |
| Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids Epirubicin, Mitomycin, Gemcitabine - Bladder Cancer, Non-muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Hospital Centre Biel/Bienne | 28 | 2026-12-01 | 2026-09-18 |
| The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial FAPI PET/CT and liquid biopsy in patients eligible for radical cystectomy, FAPI PET/CT and liquid biopsy in patients eligible for conservative treatment - Bladder Cancer | Phase 2 | Not yet recruiting | Chiti Arturo | 262 | 2026-09-01 | 2025-12-02 |
| SL-28 for Advanced Solid Tumours SL-28 - Head & Neck Cancer, Pancreas Carcinoma | Phase 1 / Phase 2 | Recruiting | Second Life Therapeutics | 60 | 2026-08-14 | 2026-09-15 |
| Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer Disitamab Vedotin (RC48), Toripalimab, Transurethral Resection of Bladder Tumor - Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer | Phase 2 / Phase 3 | Not yet recruiting | Tianjin Medical University Second Hospital | 114 | 2026-08-01 | 2026-08-10 |
| Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01) Sacituzumab Tirumotecan, MMAE-based ADC, Sacituzumab Tirumotecan (Observational Cohort) - Bladder Cancer, Metastatic Urothelial Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 75 | 2026-07-15 | 2026-06-23 |
| Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC) Neoadjuvant Therapy, Upfront radical cystectomy - Bladder Cancer | Phase 2 | Recruiting | Rutgers, The State University of New Jersey | 60 | 2026-07-10 | 2026-08-13 |
| PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer PTC guided individualized neoadjuvant therapy - Bladder Cancer | Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 35 | 2026-07-01 | 2026-07-08 |
| Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer Disitamab vedotin, Toripalimab, Sitagliptin - Bladder Urothelial Carcinoma, Bladder Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2026-07-01 | 2026-07-21 |
| Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC Intravesical Gemcitabine and Docetaxel - Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Recruiting | Michael A. O'Donnell | 174 | 2026-04-10 | 2026-04-17 |
| Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer Dutasteride (0.5mg) - Bladder Cancer | Phase 2 | Recruiting | Paul Toren | 95 | 2026-03-25 | 2026-03-30 |
| Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer Systemic immunotherapy - Bladder Cancer, Liquid Biopsy | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 53 | 2026-03-16 | 2026-05-26 |
| KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) MK-3120, EV, Pembrolizumab - Bladder Cancer | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 55 | 2026-02-09 | 2026-10-02 |
| EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors EBNK-001 + IL-15 + Pembrolizumab - Cancer, Sarcoma | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 83 | 2026-02-01 | 2026-02-18 |
| A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) MK-3120 - Bladder Cancer, Urinary Bladder Neoplasms | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 45 | 2025-12-09 | 2026-10-22 |
| Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor (TURBT) - Bladder Cancer | Phase 2 | Recruiting | Changhai Hospital | 31 | 2025-12-08 | 2026-07-21 |
| Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer Entinostat, Chemotherapy - Bladder Cancer, Histone Deacetylase Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 29 | 2025-12-01 | 2025-12-03 |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Dato-DXd, Carboplatin, Cisplatin - Urothelial Cancer, Bladder Cancer | Phase 2 / Phase 3 | Recruiting | Daiichi Sankyo | 630 | 2025-09-26 | 2026-08-20 |
| 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection [18F]FAPI-74, [18F]FDG - Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC) | Phase 2 | Recruiting | National Cancer Institute (NCI) | 320 | 2025-09-09 | 2026-05-19 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
Showing 20 of 321. Sign in to see all of them.
Urinary Bladder Neoplasms (321) · Carcinoma, Transitional Cell (48) · Carcinoma, Non-Small-Cell Lung (28) · Urethral Neoplasms (27) · Non-Muscle Invasive Bladder Neoplasms (25) · Ovarian Neoplasms (24) · Prostatic Neoplasms (23) · Pancreatic Neoplasms (21) · Stomach Neoplasms (20) · Neoplasms (19) · Uterine Cervical Neoplasms (19) · Breast Neoplasms (18) · Esophageal Neoplasms (18) · Kidney Neoplasms (18) · Melanoma (18)
Female Urogenital Diseases (321) · Female Urogenital Diseases and Pregnancy Complications (321) · Male Urogenital Diseases (321) · Neoplasms by Site (321) · Urogenital Diseases (321) · Urinary Bladder Diseases (318) · Urogenital Neoplasms (318) · Urologic Diseases (318) · Urologic Neoplasms (315) · Neoplasms (302) · Neoplasms by Histologic Type (109) · Neoplasms, Glandular and Epithelial (103) · Carcinoma (101) · Digestive System Diseases (42) · Digestive System Neoplasms (42)
Gemcitabine (71) · Cisplatin (51) · pembrolizumab (24) · Paclitaxel (20) · Docetaxel (18) · Carboplatin (17) · atezolizumab (16) · Cystectomy (15) · durvalumab (13) · Radiotherapy (12) · Nivolumab (11) · Doxorubicin (10) · Methotrexate (10) · Mitomycin (10) · Sunitinib (9)
Memorial Sloan Kettering Cancer Center (22) · SWOG Cancer Research Network (8) · European Organisation for Research and Treatment of Cancer - EORTC (7) · M.D. Anderson Cancer Center (7) · University of Michigan Rogel Cancer Center (7) · Dana-Farber Cancer Institute (6) · National Cancer Institute (NCI) (6) · Eastern Cooperative Oncology Group (5) · Hoffmann-La Roche (5) · Merck Sharp & Dohme LLC (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (4) · H. Lee Moffitt Cancer Center and Research Institute (4) · Radiation Therapy Oncology Group (4) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (4)
United States (189) · Canada (32) · China (31) · Spain (31) · United Kingdom (31) · France (29) · Italy (24) · Netherlands (16) · South Korea (16) · Germany (15) · Australia (13) · Belgium (12) · Denmark (8) · Japan (8) · Switzerland (8)
Dean Bajorin, MD (5) · Dean F. Bajorin, MD (4) · Arlene Siefker-Radtke, MD (3) · Robert Dreicer, MD, FACP (3) · Walter M. Stadler, MD, FACP (3) · Ajjai S. Alva, M.D. (2) · Andrea Necchi, MD (2) · Colin P. Dinney, MD (2) · Daniel P. Petrylak, MD (2) · Dr. Sandy Srinivas (2) · Gary Steinberg, MD (2) · Gustavo Leone (2)
PMID 25366678, PMID 26952546, PMID 29489427, PMID 37496366, PMID 41044356, PMID 41074972, PMID 10519404, PMID 11224527, PMID 12091876, PMID 12118019, PMID 12448661, PMID 12538684, PMID 12586807, PMID 12767086, PMID 12913696, PMID 1355007, PMID 14529770, PMID 15030777, PMID 1569695, PMID 15812833, PMID 15911238, PMID 16389183, PMID 16983508, PMID 17340590, PMID 17409436, PMID 17452976, PMID 17545536, PMID 17684133, PMID 18459175, PMID 18501081, PMID 18568488, PMID 18639470, PMID 18676751, PMID 19097774, PMID 19100600, PMID 19219610, PMID 19269798, PMID 19371909, PMID 19636012, PMID 19687335, PMID 19786668, PMID 20089114, PMID 20850152, PMID 21074799, PMID 21156335, PMID 21205754, PMID 21422406, PMID 2144854, PMID 21566413, PMID 21831711
U10CA032102 (7), 2017 (4), 2019 (4), 2023 (4), 2014 (3), 2015 (2), 2016 (2), 2018 (2), 2025 (2), 2005 (1), 2009 (1), K23CA160664 (1), P30CA006516 (1), P30CA016086 (1), P30CA043703 (1)